JP2012502064A - 酸化還元活性治療剤を用いての広汎性発達障害の処置 - Google Patents

酸化還元活性治療剤を用いての広汎性発達障害の処置 Download PDF

Info

Publication number
JP2012502064A
JP2012502064A JP2011526277A JP2011526277A JP2012502064A JP 2012502064 A JP2012502064 A JP 2012502064A JP 2011526277 A JP2011526277 A JP 2011526277A JP 2011526277 A JP2011526277 A JP 2011526277A JP 2012502064 A JP2012502064 A JP 2012502064A
Authority
JP
Japan
Prior art keywords
formula
iiic
disorder
diene
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011526277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502064A5 (https=
Inventor
ガイ エム． ミラー，
ビクトリア キーフェッツ，
Original Assignee
エジソン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エジソン ファーマシューティカルズ， インコーポレイテッド filed Critical エジソン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2012502064A publication Critical patent/JP2012502064A/ja
Publication of JP2012502064A5 publication Critical patent/JP2012502064A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/08—Dihydroxy benzenes; Alkylated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Pediatric Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011526277A 2008-09-10 2009-09-08 酸化還元活性治療剤を用いての広汎性発達障害の処置 Withdrawn JP2012502064A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19169608P 2008-09-10 2008-09-10
US61/191,696 2008-09-10
PCT/US2009/056254 WO2010030607A1 (en) 2008-09-10 2009-09-08 Treatment of pervasive developmental disorders with redox-active therapeutics

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2015055909A Division JP2015120748A (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015055908A Division JP6259410B2 (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置

Publications (2)

Publication Number Publication Date
JP2012502064A true JP2012502064A (ja) 2012-01-26
JP2012502064A5 JP2012502064A5 (https=) 2012-10-25

Family

ID=41226405

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011526277A Withdrawn JP2012502064A (ja) 2008-09-10 2009-09-08 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015055908A Active JP6259410B2 (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015055909A Withdrawn JP2015120748A (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015215902A Pending JP2016020399A (ja) 2008-09-10 2015-11-02 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2017076681A Withdrawn JP2017122125A (ja) 2008-09-10 2017-04-07 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2018116995A Pending JP2018162281A (ja) 2008-09-10 2018-06-20 酸化還元活性治療剤を用いての広汎性発達障害の処置

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015055908A Active JP6259410B2 (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015055909A Withdrawn JP2015120748A (ja) 2008-09-10 2015-03-19 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2015215902A Pending JP2016020399A (ja) 2008-09-10 2015-11-02 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2017076681A Withdrawn JP2017122125A (ja) 2008-09-10 2017-04-07 酸化還元活性治療剤を用いての広汎性発達障害の処置
JP2018116995A Pending JP2018162281A (ja) 2008-09-10 2018-06-20 酸化還元活性治療剤を用いての広汎性発達障害の処置

Country Status (8)

Country Link
US (7) US8314153B2 (https=)
EP (2) EP2344142B1 (https=)
JP (6) JP2012502064A (https=)
BR (1) BRPI0918139B1 (https=)
CA (1) CA2736250C (https=)
LT (1) LT3827815T (https=)
MX (2) MX363223B (https=)
WO (1) WO2010030607A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024161510A (ja) * 2018-10-17 2024-11-19 ピーティーシー セラピューティクス， インコーポレイテッド α－シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための２，３，５－トリメチル－６－ノニルシクロヘキサ－２，５－ジエン－１，４－ジオン

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EP2471530B1 (en) * 2005-06-01 2017-01-11 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9278085B2 (en) 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
WO2009158348A1 (en) * 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
DK2470168T3 (en) * 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
AU2011238525A1 (en) * 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
CA2797581A1 (en) * 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
US8828453B2 (en) * 2010-04-29 2014-09-09 Betul Hatipoglu Herbal-based compositions for alleviating symptoms associated with autism
EA201300215A1 (ru) * 2010-08-06 2013-07-30 Эдисон Фармасьютикалз, Инк. Лечение митохондриальных болезней нафтохинонами
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
EP2859890A3 (en) * 2011-10-31 2015-08-05 The Johns Hopkins University Methods and compositions for treatment of autism
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
AU2015364640B2 (en) 2014-12-16 2020-08-13 Ptc Therapeutics, Inc. Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
EP3390377B1 (en) 2015-12-16 2026-03-25 PTC Therapeutics, Inc. Improved methods for enriching alpha-tocotrienol from mixed tocol compositions
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN114746430B (zh) 2019-10-04 2026-01-30 康德生物医疗有限公司 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物
WO2021077034A1 (en) 2019-10-18 2021-04-22 Ptc Therapeutics, Inc. 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating hemoglobinopathy, thalassemia, sickle cell disease and other disorders
US12037350B2 (en) 2020-04-03 2024-07-16 Stealth Biotherapeutics Inc. Compositions and methods for the prevention and/or treatment of mitochondrial disease, including Friedreich's ataxia
WO2022261347A1 (en) 2021-06-10 2022-12-15 Stealth Biotherapeutics Inc. Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia
PE20240893A1 (es) 2021-07-08 2024-04-24 Ptc Therapeutics Inc Composiciones farmaceuticas que comprenden 2,3,5-trimetil-6-nonilciclohexa-2,5-dien-1,4-diona
WO2024050725A1 (en) 2022-09-07 2024-03-14 Ptc Therapeutics, Inc. Methods of producing 2, 3, 5, 6-alkyl-1, 4-benzoquinones

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115478A2 (en) * 2004-05-11 2005-12-08 The Regents Of The University Of California Methods and compositions for autism spectrum disorders
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Family Cites Families (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2856414A (en) 1958-10-14 Oxidation of alpha-tocopherol
FR5531E (fr) 1905-03-02 1906-05-02 Gaston Levy Lajeunesse Perfectionnements aux moteurs à explosions
US2398418A (en) 1943-08-27 1946-04-16 Louis F Fieser Introduction of organic radicals into quinones
FR1201200A (fr) 1958-08-08 1959-12-29 Sogespar S A Procédé de fabrication de l'alpha tocophéryl-quinone
US3071512A (en) 1959-01-26 1963-01-01 Sogespar S A New hypotensive pharmaceutical preparation containing alpha-tocopheryl-quinone
US3406188A (en) 1964-03-27 1968-10-15 Sun Oil Co Preparation of alpha-tocopherylquinone
FR5531M (https=) 1966-02-08 1967-11-13
FR1536576A (fr) 1967-08-29 1968-08-16 Eastman Kodak Co Procédés d'enrichissement et de fractionnement de mélanges à base de tocophérols
US3728363A (en) 1970-03-17 1973-04-17 Takeda Chemical Industries Ltd Quinone derivatives
US3705239A (en) 1970-10-16 1972-12-05 Roy B Gregory Pain removing compositions and methods
UST917001I4 (en) 1971-12-02 1973-12-04 Defensive publication
JPS4875564A (https=) 1972-01-08 1973-10-11
JPS4988862A (https=) 1972-12-29 1974-08-24
JPS5245698B2 (https=) 1973-04-06 1977-11-17
FR2235679B1 (https=) 1973-07-02 1978-07-21 Takeda Chemical Industries Ltd
US3909376A (en) 1974-12-04 1975-09-30 Basf Ag Electrolytic manufacture of alkyl-substituted hydroquinones
JPS52111576A (en) 1976-03-15 1977-09-19 Teijin Ltd Synthesis of 5,7,8-trimethyl-3,4-dehydrotocotrienol
JPS5938203B2 (ja) 1976-04-26 1984-09-14 エーザイ株式会社 補酵素ｑを主成分とする脳循環障害治療剤
US4153614A (en) 1978-05-12 1979-05-08 Hoffmann-La Roche Inc. Synthesis of (S)-(+)-6-hydroxy-2,5,7,8-tetramethylchroman-2-methanol and intermediates therein
LU77344A1 (https=) 1977-05-16 1979-01-19
US4201879A (en) 1977-05-16 1980-05-06 Hoffmann-La Roche Inc. Hydroquinones
US4185154A (en) 1977-05-17 1980-01-22 Hoffmann-La Roche, Inc. Synthesis of vitamin E
US4127608A (en) 1977-05-17 1978-11-28 Hoffmann-La Roche Inc. Synthesis of Vitamin E
US4243598A (en) 1977-05-17 1981-01-06 Hoffmann-La Roche Inc. Synthesis of vitamin E
US4201726A (en) 1977-05-17 1980-05-06 Hoffmann-La Roche Inc. Synthesis of Vitamin E
US4310465A (en) 1977-05-17 1982-01-12 Hoffmann-La Roche Inc. Synthesis of vitamin E and quinone intermediates
JPS5640651A (en) 1979-09-12 1981-04-16 Takeda Chem Ind Ltd Quinone compound and its preparation
JPS56147746A (en) 1980-04-15 1981-11-16 Takeda Chem Ind Ltd Quinones and their preparation
JPS567734A (en) 1979-06-28 1981-01-27 Takeda Chem Ind Ltd Preparation of quinone derivative
JPS567737A (en) 1979-07-02 1981-01-27 Takeda Chem Ind Ltd Physiologically active quinone and its preparation
JPS5697223A (en) 1979-12-30 1981-08-05 Takeda Chem Ind Ltd Tissue metabolism activator
JPS56140943U (https=) 1980-03-19 1981-10-24
JPH0193554A (ja) 1980-04-07 1989-04-12 Takeda Chem Ind Ltd 有機化合物
JPS56140943A (en) 1980-04-07 1981-11-04 Takeda Chem Ind Ltd Preparation of organic compound
US4393075A (en) 1980-04-14 1983-07-12 Takeda Chemical Industries, Ltd. Quinone compounds and their use in suppressing the production of SRS-A in mammals
JPS5750935Y2 (https=) 1980-06-03 1982-11-06
JPS5750935A (en) 1980-09-12 1982-03-25 Otsuka Pharmaceut Co Ltd 1,4-benzoquinone derivative
JPS57131735A (en) 1981-02-09 1982-08-14 Takeda Chem Ind Ltd Preparation of quinones
JPS6140236Y2 (https=) 1981-04-03 1986-11-17
JPS57183782A (en) 1981-04-30 1982-11-12 Sumitomo Chem Co Ltd Preparation of coumarone compound
JPS5818374A (ja) 1981-07-27 1983-02-02 Nitsusui Seiyaku Kk エイコサペンタエン酸トコフエロ−ルエステル
JPS5883698A (ja) 1981-11-13 1983-05-19 Takeda Chem Ind Ltd キノン化合物およびその製造法
JPS5883698U (ja) 1981-11-27 1983-06-06 石川島播磨重工業株式会社 熱交換器
JPS6028919Y2 (ja) 1981-12-28 1985-09-02 松下電器産業株式会社 太陽熱集熱装置
JPS58193689A (ja) 1982-05-10 1983-11-11 Shiseido Co Ltd テストステロン−５α−レダクタ−ゼ阻害剤
JPS58193689U (ja) 1982-06-18 1983-12-23 三菱電機株式会社 電子部材実装装置
DK449983A (da) 1982-10-27 1984-04-28 Hoffmann La Roche Fremgangsmaade til fremstilling af optiske aktive forbindelser
CH655005A5 (it) 1983-02-16 1986-03-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
JPS59163316A (ja) 1983-03-08 1984-09-14 Eisai Co Ltd けいれんの治療・予防剤
JPS6028919A (ja) 1983-07-28 1985-02-14 Shiseido Co Ltd 皮膚外用剤
EP0134198A1 (de) 1983-08-10 1985-03-13 Ciba-Geigy Ag Verwendung von Chinonderivaten zum Schützen von Kulturpflanzen vor der phytotoxischen Wirkung von Herbiziden
JPS60197621A (ja) 1984-03-19 1985-10-07 Hohnen Oil Co Ltd コレステロ−ル低下剤
US5304658A (en) 1984-08-01 1994-04-19 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
MX9203040A (es) 1984-08-01 1992-07-31 Takeda Chemical Industries Ltd Derivados de quinona y composicion farmaceutica que los contiene.
JPS6140236A (ja) 1984-08-02 1986-02-26 Yamanouchi Pharmaceut Co Ltd ハイドロキノン誘導体
US4592867A (en) 1984-10-19 1986-06-03 Energy Conversion Devices, Inc. Synthesis method for reductant precursor
US4617317A (en) 1984-10-31 1986-10-14 Bennet Justin D Method of treating ulcerative colitis
DE3484473D1 (de) 1984-12-06 1991-05-23 Kuraray Co Chroman-verbindungen und deren herstellung.
JPH0511467Y2 (https=) 1985-03-19 1993-03-22
US5229385A (en) 1986-01-30 1993-07-20 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
JPH0788376B2 (ja) 1986-09-02 1995-09-27 エーザイ株式会社 光学活性α−トコトリエノ−ルの製造方法
GB8626344D0 (en) 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
US5057514A (en) 1987-02-03 1991-10-15 Suntory Limited Compounds effective as cerebral schemia treating agents
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5292768A (en) 1987-12-22 1994-03-08 Suntory Limited Compound effective as cerebral insufficiency improver
US5179092A (en) 1987-12-22 1993-01-12 Suntory Limited Compound effective as cerebral insufficiency improver
DK36389A (da) 1988-02-05 1989-08-06 Eastman Kodak Co Praeparat og fremgangsmaade til at forebygge vaevskader ved reperfusion
JPH01209445A (ja) 1988-02-17 1989-08-23 Fuji Photo Film Co Ltd 放射線感応性材料
JP2685785B2 (ja) 1988-03-11 1997-12-03 エーザイ株式会社 光学活性α−トコトリエノールの製造方法
EP0333472B1 (en) 1988-03-16 1997-10-08 PALM OIL RESEARCH & DEVELOPMENT BOARD Production of high concentration tocopherols and tocotrienols from palm oil by-products
DE3818696C1 (en) 1988-06-01 1989-03-30 Ems-Inventa Ag, Zuerich, Ch Process for the preparation of hydroquinone and its alkyl derivatives
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
JPH08768B2 (ja) 1989-08-24 1996-01-10 武田薬品工業株式会社 神経成長因子分泌誘導剤
FI102273B1 (fi) 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyttö
US5157132A (en) 1990-05-18 1992-10-20 Carotech Associates Integrated process for recovery of carotenoids and tocotrienols from oil
US5591772A (en) 1991-11-22 1997-01-07 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
DE69115990T2 (de) 1990-05-29 1996-05-30 Ocular Res Of Bonton Inc Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
JP3086284B2 (ja) 1991-07-05 2000-09-11 京セラミタ株式会社 電子写真感光体
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
EP0560568A3 (en) 1992-03-13 1994-06-29 Takeda Chemical Industries Ltd Hydroquinone derivatives and intermediates for production thereof
ATE271614T1 (de) 1992-05-28 2004-08-15 Ct For Molecular Biology And M Quinone-derivate zur verbesserung der zellulare bioenergie
CN1093360A (zh) 1992-10-02 1994-10-12 武田药品工业株式会社 2-o-烷基抗坏血酸的锂盐
ATE184788T1 (de) 1993-06-18 1999-10-15 Takeda Chemical Industries Ltd Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer
US5600029A (en) 1994-03-09 1997-02-04 Takeda Chemical Industries, Ltd. Process for producing DL-tocopherols and intermediates therefor
EP0708646A1 (en) 1994-05-06 1996-05-01 Alcon Laboratories, Inc. Use of vitamin e tocopheryl derivatives in ophthalmic compositions
EP0774967A1 (en) 1994-08-12 1997-05-28 Takeda Chemical Industries, Ltd. Use of quinone and hydroquinone derivatives for the teatment of cachexia
US6150402A (en) 1994-08-15 2000-11-21 Loma Linda University Medical Center Natriuretic compounds
JPH0892151A (ja) 1994-09-29 1996-04-09 Sagami Chem Res Center アリルキノンの製造方法
US5547827A (en) 1994-12-22 1996-08-20 Eastman Kodak Company Iodochloride emulsions containing quinones having high sensitivity and low fog
EP0719552A3 (en) 1994-12-26 1997-08-20 Takeda Chemical Industries Ltd Pharmaceutical composition containing a quinone derivative or the hydroquinone thereof for the treatment of dermatitis
SK282144B6 (sk) 1994-12-28 2001-11-06 Janssen Pharmaceutica N. V. Liečivo na terapeutické a profylaktické ošetrenie degeneratívnych chorôb vaskulárneho systému a nervovej sústavy, ktoré súvisia s oxidačným stresom
US20030134028A1 (en) 1995-06-01 2003-07-17 Lipton, Division Of Conopco, Inc. Fat based food products
AU6709896A (en) 1995-08-21 1997-03-12 Takeda Chemical Industries Ltd. Quinone compound, its production and use
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
ES2156633T3 (es) 1996-03-25 2001-07-01 Alcon Lab Inc Derivados del acido tiazolidina-4-carboxilico como agentes citoprotectores.
DE69712888D1 (de) 1996-07-11 2002-07-04 Takeda Chemical Industries Ltd ZUSAMMENSTELLUNGEN DIE beta-AMYLOID PROTEIN BEDINGTE ZYTOTOXIZITÄT VERHINDERN
FR2753098B1 (fr) 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
GB9702310D0 (en) 1997-02-05 1997-03-26 Univ Hertfordshire Invention
GB9722361D0 (en) 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
WO1999025336A1 (en) 1997-11-17 1999-05-27 Lipogenics, Inc. Methods for preventing restenosis using tocotrienols
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
JP2002501915A (ja) 1998-01-29 2002-01-22 イーストマン ケミカル カンパニー トコール含有混合物からのトコールの分離方法
US6433199B1 (en) 1998-05-22 2002-08-13 Shionogi Bioresearch Corporation Quinone derivatives
US5969133A (en) 1998-05-22 1999-10-19 Shiongi Bioresearch Corp. Bioreductive cytotoxic agents
WO2000006550A1 (en) 1998-07-31 2000-02-10 Nippon Soda Co., Ltd. Phenylazole compounds, process for producing the same and drugs for hyperlipemia
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
IT1304406B1 (it) 1998-10-21 2001-03-19 Danital Italia S R L Preparazione per la veicolazione di principi attivi basata su acidigrassi polinsaturi del gruppo omega 3.
US6187811B1 (en) 1998-10-28 2001-02-13 Lipogenics, Inc. Methods for treating benign prostatic hyperplasia using tocotrienols
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
DE69939457D1 (de) 1998-11-06 2008-10-16 Fuji Chem Ind Co Ltd Tocotrienole enthaltende pulver und tabletten hergestellt durch formpressen dieser pulver
US6048891A (en) 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
JP2000202297A (ja) 1999-01-20 2000-07-25 Chemiprokasei Kaisha Ltd 新規な酸化反応用触媒およびそれを用いたｐ―ベンゾキノン類の製造方法
IL144964A0 (en) 1999-02-23 2002-06-30 Pro Neuron Inc Methods of treatment of mitochondrial disorders
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
DE19916801A1 (de) 1999-04-14 2000-11-02 Bosch Gmbh Robert Spritzdüse für eine Scheibenwaschanlage
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6395915B1 (en) 1999-09-10 2002-05-28 Technikrom, Inc. Method for producing purified tocotrienols and tocopherols using liquid chromatography
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
MY127451A (en) 1999-11-04 2006-12-29 Malaysian Palm Oil Board A method of chromatographic isolation for vitamin e isomers
US8753675B1 (en) 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US6346544B2 (en) 2000-03-02 2002-02-12 Oklahoma Medical Research Foundation Desmethyl tocopherols for protecting cardiovascular tissue
WO2001092215A2 (en) 2000-06-02 2001-12-06 Us Health Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same
DE10034233A1 (de) 2000-07-14 2002-01-24 Basf Ag Tocotrienolchinon-Cyclisierungsprodukte
US6545184B1 (en) 2000-08-15 2003-04-08 The Regents Of The University Of California Practical, cost-effective synthesis of COQ10
US20030206972A1 (en) 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
MXPA03003733A (es) 2000-10-26 2004-10-15 Fournier Lab Ireland Ltd Combinacion de fenofibrato y coenzima q10 para el tratamiento de la disfuncion endotelial.
AUPR177300A0 (en) 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
AU2002236527A1 (en) 2000-11-30 2002-06-11 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
WO2002047680A2 (en) 2000-12-15 2002-06-20 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US7034054B2 (en) 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6838104B2 (en) 2000-12-20 2005-01-04 Archer Daniels Midland Company Process for the production of tocotrienols
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US6300377B1 (en) 2001-02-22 2001-10-09 Raj K. Chopra Coenzyme Q products exhibiting high dissolution qualities
US6764768B2 (en) 2001-02-28 2004-07-20 Arch Development Corporation Controlled release composition
US6964969B2 (en) 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
JP2003064017A (ja) 2001-06-12 2003-03-05 Hokko Chem Ind Co Ltd オキシスチレン誘導体の蒸留方法
US7172905B2 (en) 2001-08-07 2007-02-06 The University Of Chicago Polypeptide immobilization
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
WO2003015494A2 (en) 2001-08-21 2003-02-27 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
CA2357053A1 (en) 2001-09-04 2003-03-04 Unknown Effectiveness of a combination of antioxidant substances for the treatment of alzheimer's disease
JP2003137716A (ja) 2001-10-30 2003-05-14 Eau De Faveur:Kk 皮膚の外用剤
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
US7078541B2 (en) 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US7217133B2 (en) * 2002-04-04 2007-05-15 Jeanine Thomas Method for treating pervasive development disorder
AT414082B (de) * 2002-05-03 2006-09-15 Vis Vitalis Lizenz & Handels Verfahren zur herstellung von tocotrienol-angereicherten präparationen
US7327800B2 (en) 2002-05-24 2008-02-05 Vecima Networks Inc. System and method for data detection in wireless communication systems
DE60211875T2 (de) 2002-07-01 2006-10-26 Santhera Pharmaceuticals (Schweiz) Ag Screeningverfahren und Verbindungen zur Behandlung von Friedreich ataxia
US6953331B2 (en) 2002-08-30 2005-10-11 Extreme Components L.P. Positioning device with bearing mechanism
JP4599292B2 (ja) 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
AU2004210013A1 (en) * 2003-02-10 2004-08-19 Autogen Research Pty Ltd Therapeutic molecules
KR20060082791A (ko) 2003-06-25 2006-07-19 찰스 에르윈 코엔자임 ｑ10의 전달을 증가시키기 위한 화학적 배합물 및방법
JP2007501846A (ja) 2003-08-08 2007-02-01 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション トコトリエノールの予防的使用および治療的使用
BRPI0413742B8 (pt) 2003-08-22 2021-05-25 Antipodean Pharmaceuticals Inc composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante
US7015243B2 (en) 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
WO2005035490A2 (en) 2003-10-10 2005-04-21 Yasoo Health, Inc. PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS
EP1718163A1 (en) 2004-02-23 2006-11-08 The Texas A&M University System Antioxidant compositions and methods of use thereof
US7022441B2 (en) 2004-02-25 2006-04-04 Eastman Kodak Company Silver-free black-and-white thermographic materials containing a benzoquinone and methods of imaging
EP1731146A4 (en) 2004-03-05 2009-07-01 Morishige Fumie PREVENTION AND MEASURE AGAINST MITOCHONDRIA ILLNESS
JP5129563B2 (ja) 2004-03-18 2013-01-30 ラスク・インテレクチュアル・リザーブ・アクチェンゲゼルシャフト 視神経症に対する感受性を診断または予測するための方法
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
EP1766789B1 (en) 2004-06-22 2019-02-27 Apple Inc. Methods and systems for enabling feedback in wireless communication networks
DE102004032837A1 (de) 2004-07-02 2006-02-09 Beiersdorf Ag Verwendung von Wirkstoffkombinationen aus einem oder mehreren Biochinonen und einem oder mehreren Isoflavonen zur Verbesserung der Hautkonturen
DE602004022523D1 (de) 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
CA2599331A1 (en) 2005-02-28 2006-09-08 Meiji Dairies Corporation Hydroquinone long-chain derivatives and/or phenoxy long-chain derivatives, and pharmaceuticals preparation comprising the same
US20060241174A1 (en) 2005-04-22 2006-10-26 Anne Mueller Vitamin E tocotrienols inhibition of intracellularly obligate pathogen Chlamydia and methods of use
CA2613854A1 (en) 2005-06-30 2007-01-11 Kyowa Chemical Industry Co., Ltd. Antibacterial agent composed of silver-containing aluminum sulfate hydroxide particles and use thereof
EP1924292A2 (en) 2005-09-16 2008-05-28 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
EP1957109A2 (en) 2005-12-02 2008-08-20 Sirtris Pharmaceuticals, Inc. Modulators of cdc2-like kinases (clks) and methods of use thereof
WO2007095630A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California New ubiquinone analogs and methods of use
US9278085B2 (en) * 2006-02-22 2016-03-08 Edison Pharmaceuticals, Inc. Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
JPWO2007116750A1 (ja) 2006-03-30 2009-08-20 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びこれを用いた有機エレクトロルミネッセンス素子
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
WO2008086025A2 (en) 2007-01-10 2008-07-17 Edison Pharmaceuticals, Inc. Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
US10300034B2 (en) * 2007-02-22 2019-05-28 Children's Hospital Of Oakland Research Institute Fatty acid formulations and methods of use thereof
WO2008142433A1 (en) 2007-05-24 2008-11-27 Loders Croklaan B.V. Process for producing compositions comprising tocoherols and tocotrienols
WO2008157747A1 (en) 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
US8075909B2 (en) 2007-09-04 2011-12-13 University Of Florida Research Foundation, Incorporated Contact lens based bioactive agent delivery system
WO2009061744A2 (en) 2007-11-06 2009-05-14 Edison Pharmaceuticals, Inc. 4- (p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
WO2009088572A2 (en) 2008-01-07 2009-07-16 Centocor, Inc. Method of treating erythropoietin hyporesponsive anemias
EA023618B1 (ru) * 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. Производные (гет)арил-п-хинона для лечения митохондриальных болезней
EP2262519A4 (en) 2008-03-05 2011-03-23 Edison Pharmaceuticals Inc TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
CA2723621A1 (en) 2008-05-15 2009-11-19 Edison Pharmaceuticals, Inc Treatment of hearing and balance impairments using compounds having erythropoietin activity
WO2009143268A2 (en) 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
WO2009158348A1 (en) 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
WO2010005989A1 (en) 2008-07-09 2010-01-14 Edison Pharmaceuticals, Inc. Dermatological compositions with anti-aging and skin even-toning properties
US20100029784A1 (en) 2008-07-30 2010-02-04 Hinman Andrew W Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
WO2010014758A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
EP2344142B1 (en) * 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
BRPI0920326A2 (pt) 2008-10-09 2016-02-23 Ramscor Inc composição e método para tratamento da síndrome do olho ressecado
EP2362726B1 (en) 2008-10-14 2018-08-08 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
CA2741767C (en) 2008-10-28 2017-09-12 Ptc Therapeutics, Inc. Process for the production of alpha-tocotrienol and derivatives
EP2424360A4 (en) 2009-04-28 2012-10-03 Ampere Life Sciences Inc TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
PL2424495T3 (pl) 2009-04-28 2018-06-29 Bioelectron Technology Corporation Leczenie dziedzicznej neuropatii nerwów wzrokowych lebera i dominującego zaniku nerwu wzrokowego chinonami tokotrienolu
JP2012525397A (ja) 2009-04-28 2012-10-22 エジソン ファーマシューティカルズ， インコーポレイテッド 眼科疾患を治療するためのトコトリエノールキノンの製剤
EP2609921A1 (en) * 2009-06-25 2013-07-03 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
DK2470168T3 (en) 2009-08-26 2018-05-07 Bioelectron Tech Corp PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
US20110172312A1 (en) 2009-12-31 2011-07-14 Miller Guy M Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
SG184787A1 (en) 2010-03-09 2012-11-29 Edison Pharmaceuticals Inc Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
AU2011238525A1 (en) 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
CA2797581A1 (en) 2010-04-27 2011-11-03 Edison Pharmaceuticals, Inc. Formulations of quinones for the treatment of ophthalmic diseases
US20120101169A1 (en) 2010-07-14 2012-04-26 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
EP2601168A4 (en) 2010-08-06 2013-12-04 Ampere Life Sciences Inc TREATMENT OF MITOCHONDRIAL DISEASES BY VITAMIN K
EA201300215A1 (ru) 2010-08-06 2013-07-30 Эдисон Фармасьютикалз, Инк. Лечение митохондриальных болезней нафтохинонами
WO2012068552A1 (en) 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
US20150057363A1 (en) 2011-07-06 2015-02-26 Guy M. Miller Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
JP2014520894A (ja) 2011-07-19 2014-08-25 エジソン ファーマシューティカルズ， インコーポレイテッド 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
EA031098B1 (ru) 2013-03-08 2018-11-30 Юнилевер Н.В. Соединения резорцина для дерматологического применения
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US10189830B2 (en) 2013-03-15 2019-01-29 Bioelectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
AU2014273891A1 (en) 2013-05-31 2015-12-24 Bioelectron Technology Corporation Carboxylic acid derivatives for treatment of oxidative stress disorders
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2018081644A1 (en) 2016-10-28 2018-05-03 Bioelectron Technology Corporation Methods of analyzing p-hydroquinone levels and ratios

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115478A2 (en) * 2004-05-11 2005-12-08 The Regents Of The University Of California Methods and compositions for autism spectrum disorders
WO2006130775A2 (en) * 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
WO2007035496A1 (en) * 2005-09-15 2007-03-29 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013057682; Ｐａｔｈｏｐｈｙｓｉｏｌｏｇｙ １３, 2006, ｐ．１７１-１８１ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024161510A (ja) * 2018-10-17 2024-11-19 ピーティーシー セラピューティクス， インコーポレイテッド α－シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための２，３，５－トリメチル－６－ノニルシクロヘキサ－２，５－ジエン－１，４－ジオン

Also Published As

Publication number Publication date
EP2344142A1 (en) 2011-07-20
MX2011002318A (es) 2011-05-10
US8653144B2 (en) 2014-02-18
US20190083419A1 (en) 2019-03-21
EP2344142B1 (en) 2024-06-26
JP6259410B2 (ja) 2018-01-10
LT3827815T (lt) 2023-10-10
BRPI0918139B1 (pt) 2024-04-30
US20210128494A1 (en) 2021-05-06
JP2015120748A (ja) 2015-07-02
JP2017122125A (ja) 2017-07-13
BRPI0918139A2 (pt) 2015-12-01
US9399612B2 (en) 2016-07-26
JP2015110674A (ja) 2015-06-18
US20100063161A1 (en) 2010-03-11
US8969420B2 (en) 2015-03-03
US20150239818A1 (en) 2015-08-27
WO2010030607A1 (en) 2010-03-18
EP3827815A1 (en) 2021-06-02
MX363223B (es) 2019-03-15
CA2736250A1 (en) 2010-03-18
JP2016020399A (ja) 2016-02-04
US10105325B2 (en) 2018-10-23
US20130053450A1 (en) 2013-02-28
JP2018162281A (ja) 2018-10-18
US8314153B2 (en) 2012-11-20
CA2736250C (en) 2016-12-20
US10736857B2 (en) 2020-08-11
EP3827815B1 (en) 2023-09-06
US20140206772A1 (en) 2014-07-24
US20170157065A1 (en) 2017-06-08

Similar Documents

Publication Publication Date Title
JP6259410B2 (ja) 酸化還元活性治療剤を用いての広汎性発達障害の処置
US20120122969A1 (en) Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
Virdis et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension
EP2555765A1 (en) Treatment of ataxia telangiectasia
Ryan et al. Dermatologic conditions in Down syndrome
JP2014502974A (ja) 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物
Luo et al. The dual‐functional memantine nitrate MN‐08 alleviates cerebral vasospasm and brain injury in experimental subarachnoid haemorrhage models
JP2007501846A (ja) トコトリエノールの予防的使用および治療的使用
EP2808023A1 (en) New drug for the treatment and/or prevention of depressive disorders
HK40052915A (en) Treatment of pervasive developmental disorders with redox-active therapeutics
HK40052915B (en) Treatment of pervasive developmental disorders with redox-active therapeutics
HK1185017A (en) Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
HK1184693A (en) Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
Ikeda Biomarkers of oxidative injury in stroke patients

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150319

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150326

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20150330